Overview

• AstraZeneca and Daiichi Sankyo said TROPION-Breast02 met dual primary endpoints, showing statistically significant and clinically meaningful gains in overall survival and progression-free survival versus investigator’s-choice chemotherapy.
• The companies described Datroway as the first therapy to significantly improve overall survival in the first-line metastatic triple-negative breast cancer population for whom immunotherapy is not an option.
• The global, randomized Phase III study enrolled 644 patients across Africa, Asia, Europe, North America and South America.
• Roughly 70% of patients with metastatic triple-negative breast cancer are not candidates for immunotherapy, leaving chemotherapy as the standard first-line option.
• Full results will be presented at a medical meeting and shared with regulators as additional Phase III trials in triple-negative breast cancer continue within a broader program of more than 20 studies.